The eLAAs in Table 2 together with survivin and CML 66 have been described as ideal candidates for targeted immunotherapeutic strategy for leukemia especially AML as they are expressed in most leukemic blasts including leukemic stem cells, important for the leukemic phenotype, immunogenic and have shown clinical effective potential at peptide and protein level51. The gene discussed is BIRC5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.